Navigation Links
Pagoclone in Medical News

Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. About SANCTURA and SANCTURA XR SANCTURA(R) and SANCTURA XR(TM) belong to a class of anticholinergic compounds known as mus...

Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. About Endo Pharmaceuticals Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, ...

Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. About Endo Pharmaceuticals Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development...

Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. About Orion Corporation ( http://www.orion.fi ) Orion is a European pharmaceutical and diagnostics company which emphasises the de...

Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus To Announce First Quarter Fiscal 2008 Financial Results On Thursday, February 7, 2008

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Pharmaceuticals To Present at RBC Capital Markets Conference

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...

Indevus Pharmaceuticals to Present at Upcoming Investor Conferences

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...

With an aim to cure stuttering

...ng to the company. However, even larger trials were needed. According to New York Times, larger trials could take 2-3 years but if they succeed, pagoclone would become the first medicine for treating the problem. Research is concentrating on the idea that stammering is a neurological problem, which...
Pagoclone in Medical Technology

Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering

LEXINGTON, Mass., Sept. 26 /PRNewswire/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV ) today announced that it has signed a development, license and commercialization agreement with Teva Pharmaceutical Industries Ltd. for the exclusive, worldwide rights to pagoclone. Indevus previously anno...

Indevus Announces Presentation of Pagoclone Data at 47th Annual New Clinical Drug Evaluation Unit Meeting

Open-label Extension of Phase II Study Demonstrates Significant Additional Improvement for Patients on Pagoclone LEXINGTON, Mass., June 12, 2007 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. today announced that results from the Company's Phase II EXPRESS trial for pagoclone in persisten...

FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Safe Harbor Statement This press release contains forward-looking statements within the meaning of the Private Secur...

Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. PRO 2000 PRO 2000 (a naphthalene sulfonate polymer) is under development as a topical vaginal microbicide to prevent the s...

Indevus Pharmaceuticals Provides Update on PRO 2000 Program

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. PRO 2000 PRO 2000 (naphthalene sulfonate polymer) is a topical vaginal microbicide under development to prevent the sexual transmi...

Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Announces Submission of New Drug Application

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...

Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...

Indevus Reports Positive Data From Phase III NEBIDO Trial

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...
Pagoclone in Biological Technology

Indevus Pharmaceuticals Announces Release of 2008 Annual Report

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Contact: Michael W. Rogers EVP and Chief Financial Officer (781) 861-8444 Robin L. DeCarlo Sr. Directo...

Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results

...late stage development programs for octreotide and pagoclone are in full gear, and our successful $105 million ...ent with Teva for the development and marketing of pagoclone for the treatment of stuttering. In the first cal... Allergan -- Licensing of Worldwide Rights for pagoclone to Teva Corporate -- Issuance of U.S. Pa...

Indevus Pharmaceuticals to Present at Upcoming Investor Conferences

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. About the Jericho Road Episcopal Housing Initiative The Jericho Road Episcopal Housing Initiative creates quality homes for famili...

Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...

Indevus Announces Allergan as New Partner for SANCTURA Brand

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. About SANCTURA and SANCTURA XR SANCTURA(R) and SANCTURA(R) XR belong to a class of anticholinergic compounds known as muscarinic rec...

Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...
Other Tags
(Date:6/30/2015)... ... , ... The United Nations Foundation’s Universal Access Project, in partnership with Planned ... Youth contest today. Why We Care Youth serves as a platform for young people ... personally meant to them, and why U.S. policymakers should care about expanding access around ...
(Date:6/30/2015)... ... June 30, 2015 , ... iData ... has launched a new reimbursement insurance policy tracking and analysis service. Reimbursement ... insurance policy and rate updates in real-time from hundreds of insurance companies covering ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... Tumor Center, has joined Allegheny Health Network (AHN) as Director of ... involve the management of primary brain tumors, brain metastases, leptomeningeal disease and the ...
(Date:6/30/2015)... Louis, MO (PRWEB) , ... June 30, 2015 ... ... attorneys handling national testosterone claims alleging heart attack and stroke incidents are linked ... after Independence Day. The Case Management Conference is scheduled for July 9, 2015, ...
(Date:6/30/2015)... ... June 30, 2015 , ... The Citizens ... Danny Davis (D-IL) for writing to the Department of Health and Human Services ... behavioral healthcare system, Universal Health Services (UHS).[1] CCHR is expanding its seven-year review ...
Breaking Medicine News(10 mins):Health News:UN Foundation, Planned Parenthood Federation of America & Sierra Club Launch Why We Care Youth to Amplify Young Voices on Critical Importance of International Reproductive Health and Contraception 2Health News:UN Foundation, Planned Parenthood Federation of America & Sierra Club Launch Why We Care Youth to Amplify Young Voices on Critical Importance of International Reproductive Health and Contraception 3Health News:UN Foundation, Planned Parenthood Federation of America & Sierra Club Launch Why We Care Youth to Amplify Young Voices on Critical Importance of International Reproductive Health and Contraception 4Health News:iData Research Introduces New Medical Insurance Reimbursement Policy & Rate Tracker Subscription Service 2Health News:Noted Duke Brain Cancer Specialist to Direct Allegheny Health Network Neuro-Oncology Program 2Health News:Noted Duke Brain Cancer Specialist to Direct Allegheny Health Network Neuro-Oncology Program 3Health News:Testosterone Lawsuit News: July Conference on Bellweather Trials 2Health News:Testosterone Lawsuit News: July Conference on Bellweather Trials 3Health News:Testosterone Lawsuit News: July Conference on Bellweather Trials 4Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 2Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 3Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 4Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 5
(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - ... partnership centralized around the incorporation of handyem,s HPC-150 ... diagnostic laboratory, the Mo-POD™. This unprecedented model of ... International Conference at the Pennsylvania ... from June 15 th to 18 th ...
(Date:6/16/2015)... Fingerprint Cards (FPC) raises the revenue guidance for ... at least 340 MSEK to that it will amount to ... growth and orders received the revenue guidance for 2015 is ... will exceed 1,500 MSEK to an updated guidance that revenue ... Due to receipt of orders of touch fingerprint sensors with ...
(Date:6/15/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... market, announces that its leading payment security technology, the Wocket® ... @ NYC June 18th. Digital Experience! @ NYC ... technology to over 300 of the top media covering the ... in New York City from 6:00 ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3
Other Contents